#interferon signature: doi.org/10.1016/j.ki...
#prognosis signature: doi.org/10.1681/asn....
#interferon signature: doi.org/10.1016/j.ki...
#prognosis signature: doi.org/10.1681/asn....
Our large kidney transcriptomic dataset of #ANCA #glomerulonephritis is now publicly available (www.ncbi.nlm.nih.gov/geo/query/ac...). Used to describe a strong renal interferon signature and a prognosis signature outperforming current classifications (links below). I hope it will be useful! 🚀
Featuring this year's #ASNJASN Trainee of the Year's award-winning manuscript: "Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated Vasculitis"
kidney.pub/JASN0779
@benoitbrilland.bsky.social @maineanjoureg.bsky.social
Using kidney transcriptomics, we identified a signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology and opening the way to precision medicine. Thank you @asnpublications.bsky.social for highlighting our work... and for making the article 🔓 OPEN ACCESS 🔓 for 1 month!!
Honored that our work on renal transcriptomics in #ANCA -associated #vasculitis was selected for the #ASNJASN Trainee of the Year award. Very proud to represent the @maineanjoureg.bsky.social and @chuangers.bsky.social !
Using kidney transcriptomics, we identified a robust 12-gene signature predicting renal survival in #ANCA #vasculitis, outperforming histopathology, and opening the way to precision medicine. Thank you for the highlight @asnpublications.bsky.social !
Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.ki... @kidneyint.bsky.social
This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️
Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation. This is why cell-specific therapies should be prioritised over blanket treatments! @kidneyint.bsky.social doi.org/10.1016/j.ki...
US 🇺🇸 nephrologists, immunologists, pathologists (et al.): there is a place for each of you in France 🇫🇷 … and especially in Angers if you like #vasculitis! www.nature.com/articles/d41...
Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️
Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Let's improve access to #KidneyTransplant! Read more in our analysis from the french REIN registry doi.org/10.1016/j.ek...
Welcome on Bluesky! @brixsilke.bsky.social @odlerb.bsky.social @thkc.bsky.social @paradise-project.bsky.social. I have included you in the « vasculits lovers » starter pack go.bsky.app/HFADD3c
Vasculitis workshop key dates
Next International #Vasculitis Workshop host @anzvasc.bsky.social is now on Bluesky! See key dates below ⬇️
PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but not sustained beyond 3 months (better for subgroup GFR 15-30?). Real PLEX effect vs convection effect? @kronbichlerlab.bsky.social www.kidney-international.org/article/S008...
Infection is the top cause of death in #ANCA -associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies www.sciencedirect.com/science/arti...
In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/
This study (aacrjournals.org/cancerimmuno...) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?
First AI-driven model for grading #ANCA -associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! www.kireports.org/article/S246...
Infections affect >50% of #ANCA -associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.au...
Brace yourself, next Vasculitis Workshop is coming! Key dates:
✅ Abstract submission: 28 March - 19 September 2025
✅ Workshop dates: 21 - 25 February 2026
📍 Melbourne, Australia
vasculitis-melbourne2026.com
Bonjour, bonjour, The Conversation France arrive sur Bluesky ! Ici, pas de breaking news tapageuses ni de buzz éphémères : on mise sur le fond, avec des articles écrits par des chercheurs et chercheuses qui savent de quoi ils parlent, en collaboration avec notre équipe d'excellents journalistes.
Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis.
▶️ higher number of relapse at 6 months for the discontinuation group
▶️ but driven by minor relapses and by subgroup not treated but Rituximab.
Presented by Pr. Peter Merkel #ACR24 (acrabstracts.org/abstract/a-m...)
Hi! Thanks for pinging. I think there is no one-size-fits-all answer. Would consider:
- risk of relapse: GPA/PR3-AAV? ANCA titer overtime? eGFR (= « tolerability » of a future relapse)? Already relapsed? CD19 not that important imo
- risk of SAE, esp. infections (frailty, comorbidities, IgG levels)
Reduced GC dose in #ANCA vasculitis: @terrierben.bsky.social confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/earl...
Welcome in @terrierben.bsky.social. The #vasculitis family is growing here on Bluesky!
Vasculitis folks are joining! Welcome in @lynnfussner.bsky.social @matsjunek.bsky.social
Moving from Twitter? Looking for #vasculits #glomerulonephritis lovers?
Starter pack (work in progress): go.bsky.app/HFADD3c. Reply or DM to be added in the list!
My take:
🔹 for detailed emerging therapies, read the #PR3 review
🔸 for detailed pathogenesis, read the #MPO review
Two recent reviews of #ANCA vasculitis with wonderful graphics, and for the first time I think, #PR3 🔹 and #MPO 🔸
phenotypes considered in parallel but SEPARATELY! A new era with individualized treatment is coming for sure!
🔹 pubmed.ncbi.nlm.nih.gov/38574742/
🔸 pubmed.ncbi.nlm.nih.gov/38574743/